

IDS  
f.led  
2/11/05

DT01 Rec'd PCT/PTC 11 FEB 2005

Sheet 1 of 1 (2/11/05)

Form PTO-1449				ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO. 107524520		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT LOIBNER, Hans et al.			
				FILING DATE February 11, 2005	GROUP		
U. S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
FOREIGN PATENT DOCUMENTS							
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION
							YES
/BD/	WO 0069460	A	2000-11-23	WIPO			
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)							
<del>Nakashio et al. "Peritoneal Dissemination is Inhibited by Treatment With Antibodies Against CD44H, Betal, Integrin, and Carcinostatic ..." International Journal of Oncology, Vol. 10, No. 2, 1997, pp. 355-362</del>							
<del>Schneider-Gaedcke et al. "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours" European Journal of Cancer, Vol. 31A, No 7-8, 1995, pp. 1326-1330</del>							
<del>Reithmueller et al., "Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial" Journal of Clinical Oncology, Vol. 16, No. 5, May 1998, pp. 1788-1794</del>							
EXAMINER /Brad Duffy/				DATE CONSIDERED 7/23/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

IDS  
filed  
8/22/05

Sheet 1 of 2 (08/18/05)

Form PTO-1449		ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO. 10/524,520
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		APPLICANT LOIBNER, Hans et al.	
		FILING DATE February 11, 2005	GROUP

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	KIND	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/BD/	US 2001/0006618	A1	2001-07-05	Goldenberg			
/BD/	US 4,643,971		1987-02-17	Frader et al.			
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

**FOREIGN PATENT DOCUMENTS**

Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
/BD/	WO 01/23005	A1	2001-04-05	WIPO				
	WO 00/69460	A1	2000-11-23	WIPO				
	WO 01/03738	A1	2001-01-18	WIPO				
	WO 93/21940	A1	1993-11-11	WIPO				
↓	EP 1140168	B1	2002-06-26	EPO				

**OTHER DOCUMENTS** (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

(Abstract) Swayne L.C. et al. " SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases" Journal Article, Vol. 16, No. 11, November 1991, pp. 849-852
(Abstract) Edington M.D. " Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium-111 labeled monoclonal antibody to CEA" Journal Article, Vol. 104, No. 6, December 1998, pp. 1004-1010
(Abstract) Cote R.J. et al. " Intraoperative monoclonal antibody CC49" Journal Article, Vol. 77, No. 4, February 15, 1996, pp. 613-620
(Abstract) Bechner P. et al. " Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer" Journal Article, Vol. 34, No. 1, February 1995, pp. 8-14

EXAMINER /Brad Duffy/	DATE CONSIDERED 7/23/2007
--------------------------	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT LOIBNER, Hans et al.	
(Use several sheets if necessary)		FILING DATE February 11, 2005	GROUP
<b>OTHER DOCUMENTS</b> (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposia, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)			
J.P. Chippaux and M. Goyffon. "Venoms, Antivenoms and Immunotherapy" Journal Toxicon, Vol.36, No. 6, May 7,1997, pp. 823-846			
G. Riethmüller et.al. "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial" Journal of Clinical Oncology, Vol.16, No.5, May 1998, pp.1788-1794			
Tatsuaki, Nakashita et al. " Peritoneal dissemination is inhibited by treatment with antibodies against CD44H, B1 integrin, carcinostatic agents in NUGC-4 human gastric cancer cells" International Journal of Oncology, Vol. 10, 1997, pp.355-362			
Barchi, Joseph J. Jr. " Emerging Roles of Carbohydrates and Glycomimetics in Anticancer Drug Design" Current Pharmaceutical Design, Vol. 6,2000,pp.485-501			
Ben-Yedidya Tamar and Arnon Ruth." Design of Peptide and Polypeptide vaccines" Biotechnology, Vol.8, 1997, pp.442-448			
Casadevall, Arturo and Scharff Matthew D. " Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases" Clinical Infectious Diseases, Vol.21,1995,pp.150-161			
Glennie, Martin J. and Johnson, Peter W.M. " Clinical trials of antibody therapy" Journal Immunology Today, Vol.21, no. 8, August 2000, pp.403-410			
Gollogly, V. Castronovo. " A possible role for the alpha 1-3 galactosyl epitope and natural anti-gal antibody in ontogenesis" Neoplasma Journal, Vol.43, No.5, 1996, pp.285- 289			
Herlyn, Dorothy and Birebent Brigitte. " Advances in cancer vaccine development" the Finnish Medical Society Duodecim Vol.31,1999, pp.66-78			
Lewis, Jonathan J. and Houghton, Alan N. " Definition of tumor antigens suitable for vaccine construction" Cancer Biology, Vol.6,1995,pp.321-327			
Melief, Cornelis J.M. et al. " Peptide-based cancer vaccines" Current Opinion in Immunology, Vol.8, 1996, pp.651-657			
Miyake, Masayuki. et. al. " Correlation of Expression of H/Ley/Leb Antigens with Survival in Patients with Carcinoma of the Lung" The New England Journal of Medicine, July 2, 1992,pp.14-18			
Orntoft, F. Torben and Vestergaard, Else Marie. " Clinical aspects of altered glycosylation of glycoproteins in cancer" Electrophoresis Journal, Vol.20, 1999, pp.362-371			
Scott, Andrew M. and Welt, Sydney. "Antibody-based immunological therapies" Journal of Current Opinion on Immunology, Vol. 9. 1997, pp.717-722			
Weitz, Jürgen MD and Herfarath, Christian MD. " Surgical Strategies and Minimal Residual Disease Detection" Seminars in Surgical Oncology, Vol.20, 2001 pp.329-333.			
EXAMINER	DATE CONSIDERED		
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

IRS/sd